Zhejiang Ausun Pharmaceutical Co., Ltd. (SHA:603229)
China · Delayed Price · Currency is CNY 7.52
-0.19 (-2.46%)
Sep 11, 2026, 3:00 PM CST
SHA:603229 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 6,205 | 8,217 | 8,295 | 7,834 | 9,564 | 10,451 | |
Market Cap Growth | -32.39% | -0.94% | 5.87% | -18.09% | -8.49% | 19.25% |
Enterprise Value | 5,562 | 7,458 | 7,572 | 7,115 | 9,183 | 9,848 |
Last Close Price | 7.52 | 9.85 | 9.81 | 9.15 | 11.71 | 12.78 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 73.49 | 62.93 | 40.11 | 30.86 | 40.64 | 71.62 |
Forward PE | - | 34.21 | 25.95 | 22.58 | 34.87 | 54.34 |
PS Ratio | 7.97 | 10.37 | 10.43 | 9.59 | 12.51 | 18.35 |
PB Ratio | 2.60 | 3.62 | 3.65 | 3.66 | 6.55 | 8.33 |
P/TBV Ratio | 2.77 | 3.88 | 3.92 | 3.94 | 7.36 | 9.58 |
P/FCF Ratio | - | 157.82 | 124.50 | 134.20 | - | - |
P/OCF Ratio | 90.26 | 52.50 | 46.62 | 35.32 | 79.33 | 60.10 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 7.14 | 9.41 | 9.52 | 8.71 | 12.01 | 17.29 |
EV/EBITDA Ratio | 32.04 | 39.24 | 30.52 | 24.96 | 38.32 | 54.04 |
EV/EBIT Ratio | 60.47 | 63.63 | 41.05 | 29.10 | 44.75 | 64.70 |
EV/FCF Ratio | - | 143.25 | 113.66 | 121.89 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.15 | 0.20 | 0.12 | 0.14 | 0.17 | 0.09 |
Debt / EBITDA Ratio | 2.08 | 2.39 | 1.10 | 1.06 | 1.01 | 0.60 |
Debt / FCF Ratio | - | 8.77 | 4.09 | 5.19 | - | - |
Net Debt / Equity Ratio | -0.27 | -0.34 | -0.36 | -0.38 | -0.25 | -0.45 |
Net Debt / EBITDA Ratio | -3.73 | -4.05 | -3.33 | -2.88 | -1.55 | -3.10 |
Net Debt / FCF Ratio | 23.49 | -14.79 | -12.40 | -14.06 | 2.45 | 4.12 |
Asset Turnover | 0.25 | 0.26 | 0.27 | 0.31 | 0.37 | 0.35 |
Inventory Turnover | 1.03 | 0.97 | 0.98 | 1.09 | 1.32 | 1.21 |
Quick Ratio | 2.27 | 1.87 | 1.92 | 1.63 | 1.01 | 1.40 |
Current Ratio | 2.96 | 2.47 | 2.53 | 2.17 | 1.53 | 1.92 |
Return on Equity (ROE) | 3.37% | 5.75% | 9.37% | 14.09% | 17.33% | 12.25% |
Return on Assets (ROA) | 1.85% | 2.42% | 3.89% | 5.80% | 6.17% | 5.91% |
Return on Invested Capital (ROIC) | 5.34% | 7.54% | 11.48% | 17.71% | 21.20% | 24.91% |
Return on Capital Employed (ROCE) | 3.70% | 5.00% | 8.00% | 11.20% | 13.10% | 11.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.31% | 1.59% | 2.49% | 3.24% | 2.46% | 1.40% |
FCF Yield | -0.44% | 0.63% | 0.80% | 0.74% | -1.58% | -1.31% |
Dividend Yield | 0.80% | 0.65% | 1.02% | 1.01% | 0.49% | 0.29% |
Payout Ratio | 114.40% | 69.41% | 40.73% | 22.63% | 16.00% | 13.69% |
Buyback Yield / Dilution | 5.90% | 1.34% | -0.99% | -1.92% | -1.16% | -6.67% |
Total Shareholder Return | 6.70% | 1.99% | 0.03% | -0.92% | -0.67% | -6.38% |